草氨酸钠通过抑制肺泡II型上皮细胞衰老减轻小鼠矽肺纤维化

Oxamate alleviates silicotic fibrosis in mice by inhibiting senescence of alveolar type II epithelial cells

  • 摘要:
    背景 肺泡II型上皮细胞衰老是矽肺纤维化进展的重要驱动因素,草氨酸钠对肺泡II型上皮细胞衰老的调节作用尚不清楚。
    目的 探讨乳酸脱氢酶抑制剂草氨酸钠是否可通过抑制肺泡II型上皮细胞衰老减轻小鼠矽肺纤维化。
    方法 本研究分为体内实验和体外实验两部分。体内研究中将40只SPF级雄性C57BL/6J随机分为4组,每组10只,实验分组为对照组、矽肺模型组、草氨酸钠低剂量治疗组、草氨酸钠高剂量治疗组。采用一次性气管灌注SiO2悬浊液50 μL(100 mg·mL−1)制备矽肺小鼠模型;采用腹腔注射草氨酸钠100 μL(225 mmol·L−11125 mmol·L−1)制备草氨酸钠治疗模型。体外研究中采用SiO2诱导MLE-12小鼠肺泡II型上皮细胞,实验分组为①不同浓度SiO2诱导组:对照组、50 μg·mL−1 SiO2组、100 μg·mL−1 SiO2组和200 μg·mL−1 SiO2组;②草氨酸钠治疗组:对照组、SiO2组(100 μg·mL−1)、草氨酸钠低剂量(25 mmol·L−1)治疗组和草氨酸钠高剂量(50 mmol·L−1)治疗组。采用苏木素-伊红(HE)染色观察肺组织病理学形态;天狼星红染色观察肺组织胶原蛋白沉积;采用免疫荧光染色观察表面活性蛋白C前体(Pro-SPC)和β-半乳糖苷酶(β-galactosidase)的阳性共表达;采用免疫荧光染色观察MLE-12细胞β-galactosidase的阳性表达;采用免疫印迹法检测I型胶原(CoL I)、纤维连接蛋白1(FN1)、己糖激酶2(HK2)、肌肉丙酮酸激酶同工酶2(PKM2)、乳酸脱氢酶A(LDHA)、磷酸化毛细血管扩张性共济失调(p-ATR)、细胞周期蛋白依靠性激酶抑制剂p21和p16的蛋白表达水平。
    结果 与对照组相比较,矽肺模型组和SiO2诱导的MLE-12细胞中,HK2、PKM2、LDHA、p-ATR、p21和p16的蛋白表达水平均上调(P<0.05)。体内研究显示,与对照组相比较,矽肺模型组中,矽结节面积,胶原蛋白沉积面积,β-galactosidase阳性细胞数占比,CoL I、FN1、LDHA、p-ATR、p21和p16的蛋白表达水平均上调(P<0.05);与矽肺模型组相比较,草氨酸钠治疗组中矽结节面积,胶原蛋白沉积面积,β-galactosidase阳性细胞数占比,CoL I、FN1、LDHA、p-ATR、p21和p16的蛋白表达水平均下调,且草氨酸钠高剂量治疗组效果优于草氨酸钠低剂量治疗组(P<0.05)。体外研究显示,与对照组相比较,SiO2诱导组中,β-galactosidase阳性细胞数占比、p-ATR、p21和p16的蛋白表达水平均上调(P<0.05);与SiO2组相比较,草氨酸钠治疗组中β-galactosidase阳性细胞数占比、LDHA、p-ATR、p21和p16的蛋白表达水平均下调,且草氨酸钠高剂量治疗组效果优于草氨酸钠低剂量治疗组(P<0.05)。
    结论 乳酸脱氢酶抑制剂草氨酸钠可通过抑制肺泡II型上皮细胞衰老以减轻小鼠矽肺纤维化。

     

    Abstract:
    Background The senescence of alveolar type II epithelial cells is an important driving factor for the progression of silicotic fibrosis, and the regulatory effects of oxamate on the senescence of alveolar type II epithelial cells is still unclear.
    Objective To explore whether lactate dehydrogenase inhibitor oxamate can alleviate silicotic fibrosis in mice by inhibiting senescence of alveolar type II epithelial cells
    Methods This study was divided into two parts: in vivo experiments and in vitro experiments. In the first part, forty SPF C57BL/6J male mice were randomly divided into four groups with 10 in each group: control group, silicosis model group, low-dose oxamate treatment group, and high-dose oxamate treatment group. The silicotic mouse model was established by intratracheal instillation of 50 μL SiO2 suspension (100 mg·mL−1). The treatment models were prepared by intraperitoneal injection of 100 μL oxamate (225 mmol·L−1 and 1125 mmol·L−1). In the second part, induction of MLE-12 mouse alveolar type II epithelial cells was conducted with SiO2. The in vitro experimental groups were ① SiO2 induction groups: control group, 50 μg·mL−1 SiO2 group, 100 μg·mL−1 SiO2 group, and 200 μg·mL−1 SiO2 group, and ② oxamate treatment groups: control group, SiO2 group (100 μg·mL−1), low-dose oxamate (25 mmol·L−1) treatment group, and high-dose oxamate (50 mmol·L−1) treatment group. Pathological morphology of lung tissues was evaluated after hematoxylin-eosin (HE) staining; deposition of collagen in lung tissues was evaluated after sirius red staining; positive co-expression of prosurfactant protein C (Pro-SPC) and β-galactosidase was detected by immunofluorescence staining; positive expression of β-galactosidase in MLE-12 cells was detected by immunofluorescence staining. The protein expression levels of collagen type I (CoL I), fibronectin1 (FN1), hexokinase 2 (HK2), pyruvate kinase isozyme type M2 (PKM2), lactate dehydrogenase A (LDHA), p-ataxia telangiectasia and Rad3-related kinase (ATR), and cyclin-dependent kinase inhibitors p21, and p16 were detected by Western blotting.
    Results Compared with the control group, the protein expression levels of HK2, PKM2, LDHA, p-ATR, p21, and p16 were significantly upregulated in the silicosis model group and the SiO2-induced MLE-12 cells (P<0.05). The in vivo studies showed that, compared with the control group, the silicon nodule area, the collagen deposition area, the proportion of β-galactosidase positive cells, and the protein expression levels of CoL I, FN1, LDHA, p-ATR, p21, and p16 were significantly upregulated in the silicosis model group (P<0.05). Compared with the silicosis model group, the oxamate treatment groups showed significant downregulation of the silicon nodule area, the collagen deposition area, the proportion of β-galactosidase positive cells, and the the CoL I, FN1, LDHA, p-ATR, p21, and p16 protein expression levels, and the high-dose oxamate treatment group showed a higher efficacy on these indicators than the low-dose oxamate treatment group (P<0.05). The in vitro studies showed that, compared with the control group, the proportion of β-galactosidase positive cells and the protein expression levels of p-ATR, p21, and p16 were significantly upregulated in the SiO2-induced group (P<0.05). Compared with the SiO2 group, the proportion of β-galactosidase positive cells and the LDHA, p-ATR, p21 and p16 protein expression levels were significantly downregulated in the oxamate treatment groups, and the high-dose oxamate treatment group showed a higher efficacy on these indicators than the low-dose oxamate treatment group (P<0.05).
    Conclusion Lactate dehydrogenase inhibitor oxamate can alleviate silicotic fibrosis in mice by inhibiting the senescence of alveolar type II epithelial cells.

     

/

返回文章
返回